熱門:

2018年8月16日

Frank Ching EJ Insight

China vaccine scandal shows, once again, why HK is different

In mid-July, China’s state drug administration ordered Changsheng Bio-technology, a company headquartered in Changchun in northeastern China, to stop production of rabies vaccines after it uncovered evidence of forged data. At about the same time, the company was fined 3.4 million yuan (US$502000) for production of inferior DPT vaccines last year.

As soon as the news got out, mothers on the mainland reacted. One Shenzhen resident, 33-year-old Emily Liu, made an urgent appointment in Hong Kong for her 5-year-old son to be vaccinated. Within 48 hours, he had received a booster shot of a four-in-one vaccine against diphtheria, tetanus, whooping cough and polio.

“I feel a bit ashamed about crossing the border to snap up a vaccine,” the South China Morning Post quoted Liu as saying, “and I totally understand if Hong Kong people resent us for doing it, but it’s just what I’ve got to do as a mother.” And if Hong Kong should impose restrictions on non-residents, she said, she was prepared to travel to Japan or Taiwan to have her son vaccinated.

She said the Hong Kong clinic was inundated with calls from mainland China while she was there. In all likelihood, the callers were mothers like her, who wanted protection for their children.

The vaccine crisis was the latest product safety scandal in China. The Chinese government promised quick action.

Premier Li Keqiang pledged in a statement on July 22 that the government “will resolutely crack down on illegal and criminal acts that endanger the safety of peoples’ lives, resolutely punish lawbreakers according to the law, and resolutely and severely criticize dereliction of duty in supervision.”

Unfortunately, the statement reminded many people of a similar pledge made in 2016 during another vaccine scandal. At that time, it was found that US$90 million worth of expired or improperly stored vaccines were sold by a mother-and-daughter team to 24 provinces from their base in Shandong over a five-year period.

While promising to crack down on the current perpetrators, Chinese authorities have at the same time issued a directive forbidding any reporting on the issue. This is not likely to increase public confidence. After all, letting independent journalists do their job is the best way of keeping officials honest, unless there is something someone high up doesn’t want the public to know.

One of the biggest problems is a lack of political will. The Communist Party seems to have just one top priority, which is to ensure that it not only remains in power but cannot be questioned. To ensure this priority, the propaganda organs politicize every issue and make it difficult for professionals to do their work.

That means the health needs of the Chinese people suffer. Product scandals, like those this year and in 2016, will continue to occur.

In 2016, too, mainland mothers flooded across the border seeking vaccinations for their children. Hong Kong imposed on public health clinics a maximum of 120 vaccinations for non-local children per month. Private clinics were not affected.

Not only do scandals recur, some of the players remain the same too. Thus, during the milk scandal of 2008--when infant formula was adulterated with the chemical melamine to give the impression of a higher protein level, resulting in six deaths and thousands hospitalized--one of the food safety officials penalized was Sun Xianze. He was issued a demerit, the lightest punishment of a group of officials.

Sun was soon climbing up the bureaucratic ladder again and, in 2012, he was appointed deputy director of the State Food and Drug Administration. He was given the job of overseeing drug safety and it was during his watch that the Shandong-based mother-daughter team, which involved more than 200 accomplices, was operating.

Even the Changsheng Bio-Technology case occurred on his watch. It was discovered last November, though not announced until last month, that Changsheng Bio-Technology had produced and sold more than 250000 inferior DPT vaccines, and that another company, Wuhan Institute of Biological Products, had produced and distributed 400520 inferior DPT vaccines, most of which were administered to children as young as three months old.

But in March 2018, before the latest crisis, Sun retired, seemingly untainted by any whiff of scandal.

If there is a silver lining behind China’s latest product safety scandal, it is that Hong Kong is again shown as far from being “just another Chinese city.” And, it would seem, people on the mainland know this well. They may not trust their own government, but they trust Hong Kong. And they know where to go if they want safe food, milk powder and medicine.

更多精彩英文內容,請瀏覽以下網址:www.ejinsight.com

訂戶登入

回上

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。

You are currently at: www.hkej.com
Skip This Ads